Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with 89Zr-oxine for Medium-Term In Vivo Cell Tracking
Open Access
Abstract
Regulatory T cells (Tregs) are a promising candidate cell therapy to treat autoimmune diseases and aid the longevity of transplanted solid organs. Despite increasing numbers of clinical trials using human Treg therapy, important questions pertaining to their in vivo fate, distribution, and function remain unanswered. Treg accumulation in relevant tissues was found to be crucial for Treg therapy efficacy, but existing blood-borne biomarkers are unlikely to accurately reflect the tissue state. Non-invasive Treg tracking by whole-body imaging is a promising alternative and can be achieved by direct radiolabelling of Tregs and following the radiolabelled cells with positron emission tomography (PET). Our goal was to evaluate the radiolabelling of polyclonal Tregs with 89Zr to permit their in vivo tracking by PET/CT for longer than one week with current preclinical PET instrumentation. We used [89Zr]Zr(oxinate)4 as the cell-labelling agent and achieved successful radiolabelling efficiency of human Tregs spanning 0.1–11.1 Bq 89Zr/Treg cell, which would be compatible with PET tracking beyond one week. We characterized the 89Zr-Tregs, assessing their phenotypes, and found that they were not tolerating these intracellular 89Zr amounts, as they failed to survive or expand in a 89Zr-dose-dependent manner. Even at 0.1 Bq 89Zr per Treg cell, while 89Zr-Tregs remained functional as determined by a five-day-long effector T cell suppression assay, they failed to expand beyond day 3 in vitro. Moreover, PET imaging revealed signs of 89Zr-Treg death after adoptive transfer in vivo. In summary, 89Zr labelling of Tregs at intracellular radioisotope amounts compatible with cell tracking over several weeks did not achieve the desired outcomes, as 89Zr-Tregs failed to expand and survive. Consequently, we conclude that indirect Treg labelling is likely to be the most effective alternative method to satisfy the requirements of this cell tracking scenario.Keywords
Funding Information
- British Heart Foundation (RG/13/12/30395, MR/J006742/1, C48390/A21153, WT203148/Z/16/Z)
- Medical Research Council (RG/13/12/30395, MR/J006742/1, C48390/A21153, WT203148/Z/16/Z)
- Cancer Research UK (RG/13/12/30395, MR/J006742/1, C48390/A21153, WT203148/Z/16/Z)
- Wellcome/EPSRC Centre for Medical Engineering (RG/13/12/30395, MR/J006742/1, C48390/A21153, WT203148/Z/16/Z)
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London and/or the NIHR Clinical Research Facility (RG/13/12/30395, MR/J006742/1, C48390/A21153, WT203148/Z/16/Z)
This publication has 41 references indexed in Scilit:
- FOXP3: Genetic and epigenetic implications for autoimmunityJournal of Autoimmunity, 2013
- Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapyNephrology Dialysis Transplantation, 2011
- Human FoxP3+ regulatory T cells in systemic autoimmune diseasesAutoimmunity Reviews, 2011
- In vivo biodistribution and accumulation of 89Zr in miceNuclear Medicine and Biology, 2011
- Human Regulatory T Cells with Alloantigen Specificity Are More Potent Inhibitors of Alloimmune Skin Graft Damage than Polyclonal Regulatory T CellsScience Translational Medicine, 2011
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kineticsBlood, 2011
- Zirconium: Biomedical and Nephrological ApplicationsASAIO Journal, 2010
- Guidelines for the labelling of leucocytes with 111In-oxineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cellsClinical Immunology, 2009
- Contrasting CD25hiCD4+T Cells/FOXP3 Patterns in Chronic Rejection and Operational Drug-Free ToleranceTransplantation, 2006